| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $11.9M | -6.3% |
| SG&A Expense | $9.9M | -4.5% |
| Operating Income | -$21.8M | +5.5% |
| Net Income | $1.4M | +104.8% |
| EPS (Basic) | $0.19 | +104.1% |
| EPS (Diluted) | $0.19 | +104.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $21.4M | -47.8% |
| Current Assets | $22.3M | -47.0% |
| Total Assets | $37.1M | -34.7% |
| Current Liabilities | $2.8M | -15.1% |
| Total Liabilities | $62.8M | -26.4% |
| Stockholders' Equity | -$25.7M | +9.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$19.6M | -32.2% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $19.6M | +0.0% |